Global Markets for Diabetes Therapeutics and Diagnostics
Report Highlights
The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.
Report Includes
- 162 data tables and 63 additional tables
- An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
- Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
- In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
- Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
- Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
- Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
- Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca
Report Scope
This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.
Frequently Asked Questions (FAQs)
Analyst Credentials
Bejini Sandeep Kumar– Assistant Manager - Life Sciences Research
Sandeep Kumar has over 11 years of experience in pharmaceutical and medical equipment research and consulting. With expertise lying in business research studies, such as industry analysis, strategic and financial analysis, opportunity assessment and competitor intelligence. Sandeep has extensive experience in market research and analysis, specializing in healthcare, medical devices, biotechnology, healthcare IT, pharmaceuticals, and others. He holds a bachelor’s degree in Biotechnology and a Post Graduate degree in Business Management from Liverpool John Moores University (LJMU).
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2022 |
| Forecast period considered | 2023-2028 |
| Base year market size | $97.3 billion |
| Market size forecast | $132.0 billion |
| Growth rate | CAGR of 5.2% for the forecast period of 2023-2028 |
| Units considered | $ Millions |
| Segments covered | Product Group, End-User, and Region |
| Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW). |
| Countries covered | U.S., Canada, Mexico, France, Germany, U.K., Italy, Spain, China, India, and Japan |
| Key Market Drivers |
|
| Companies studied |
|
Report Highlights
The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
Report Includes
- An overview of the global market for diabetes
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Analysis of the devices and instruments used in the diagnosis and monitoring of diabetes
- A close look at major forces contributing to the vigorous growth of the diabetes market
- Evaluation of other factors influencing the market such as health care policies, demographics, and the wider economic environment
- Discussion covering companies in the relevant pharmaceutical and medical industries through company profiles of many leading players in the field
Report Highlights
The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012. Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.
Report Highlights
-
The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
-
Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR).
-
Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.
Report Highlights
- The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
- The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
- Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
Report Highlights
-
The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
-
Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
-
Insulin was 33% of the market in 2000 and is expected to hold on to that share.
-
Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
-
The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.